SCHEMBL547749

SCHEMBL547749

Cc1ccc(C(=S)S)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.48
CES2 O00748 3/20 0.48
CES1 P23141 3/20 0.48
LMNA P02545 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.46
TDP1 Q9NUW8 3/20 0.44
ACHE P22303 2/20 0.44
PKM P14618 2/20 0.42
HTT P42858 2/20 0.42
ATM Q13315 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42
HPGD P15428 2/20 0.42
NLRP1 Q9C000 1/20 0.42
GAA P10253 1/20 0.42
MEN1 O00255 1/20 0.42
NTSR1 P30989 1/20 0.42
KMT2A Q03164 1/20 0.42
HDAC1 Q13547 2/20 0.41
HDAC6 Q9UBN7 2/20 0.41
SRD5A2 P31213 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2773466 0.85 CA1 (0.36) SMN1; SMN2HTT
SCHEMBL8716212 0.78 ESR1 (0.33) SMN1; SMN2HTT
SCHEMBL18668110 0.77 ESR1 (0.35) ALDH1A1LMNASMN1; SMN2MEN1KMT2A
SCHEMBL4460667 0.77 ALDH1A1 (0.52) ALDH1A1CES2CES1LMNASMN1; SMN2
SCHEMBL499513 0.74 ALDH1A1 (0.50) ALDH1A1CES2CES1LMNASMN1; SMN2
SCHEMBL6688433 0.74 MAPT (0.47) ALDH1A1LMNASMN1; SMN2ACHEPKM
SCHEMBL5179861 0.74 ALDH1A1 (0.50) ALDH1A1CES2CES1LMNASMN1; SMN2
SCHEMBL1411939 0.74 ALDH1A1 (0.55) ALDH1A1CES2CES1LMNASMN1; SMN2
SCHEMBL8713246 0.74 MAPT (0.50) ALDH1A1LMNASMN1; SMN2TDP1HPGD
SCHEMBL20221449 0.72 ALDH1A1 (0.48) ALDH1A1CES2CES1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230119325-A1 GLYCOTARGETING THERAPEUTICS ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) (CH) 2023-04-20 US disclosed
US-10976267-B2 Method of analyzing diffraction data obtained from a single crystal of a porous compound and a compound for which a structure is to be determined JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2021-04-13 US disclosed
US-10953101-B2 Glycotargeting therapeutics ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) (CH) 2021-03-23 US disclosed
US-10684198-B2 Guest-compound-enveloping polymer-metal-complex crystal, method for producing same, method for preparing crystal structure analysis sample, and method for determining molecular structure of organic compound JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2020-06-16 US disclosed
US-10487420-B2 Single crystal of porous compound, method for assessing quality of single crystal, method for preparing solution including compound to be analyzed, method for producing crystal structure analysis sample, and method for determining molecular structure of compound to be analyzed THE UNIVERSITY OF TOKYO (JP) 2019-11-26 US disclosed
US-10309035-B2 Method of preparing sample for crystal structure analysis, method of determining absolute configuration of chiral compound, and polynuclear metal complex monocrystal THE UNIVERSITY OF TOKYO (JP) 2019-06-04 US disclosed
US-20190137367-A1 GUEST-COMPOUND-ENVELOPING POLYMER-METAL-COMPLEX CRYSTAL, METHOD FOR PRODUCING SAME, METHOD FOR PREPARING CRYSTAL STRUCTURE ANALYSIS SAMPLE, AND METHOD FOR DETERMINING MOLECULAR STRUCTURE OF ORGANIC COMPOUND JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2019-05-09 US disclosed
US-10190952-B2 Guest-compound-enveloping polymer-metal-complex crystal, method for producing same, method for preparing crystal structure analysis sample, and method for determining molecular structure of organic compound JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2019-01-29 US disclosed
EP-3269849-A1 SINGLE CRYSTAL OF POROUS COMPOUND, METHOD FOR ASSESSING QUALITY OF SINGLE CRYSTAL, METHOD FOR PREPARING SOLUTION INCLUDING COMPOUND TO BE ANALYZED, METHOD FOR PRODUCING CRYSTAL STRUCTURE ANALYSIS SAMPLE, AND METHOD FOR DETERMINING MOLECULAR STRUCTURE OF COMPOUND TO BE ANALYZED The University of Tokyo (JP) 2018-01-17 EP disclosed
US-20170219500-A1 DIFFRACTION DATA ANALYSIS METHOD, COMPUTER PROGRAM, AND RECORDING MEDIUM JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2017-08-03 US disclosed
EP-0220273-A4 SYNTHETIC ANTIGENS FOR THE DETECTION OF AIDS-RELATED DISEASE. GENETIC SYSTEMS CORP (US) 1989-10-04 EP disclosed
WO-1989003813-A1 ANTI-RETROVIRAL AGENT GENELABS INCORPORATED (US) 1989-05-05 WO disclosed
WO-1989003420-A1 ANTI-RETROVIRAL AGENT GENELABS INCORPORATED (US) 1989-04-20 WO disclosed
WO-1989003221-A1 ANTISYNCYTIAL AGENT GENELABS INCORPORATED (US) 1989-04-20 WO disclosed
EP-0284383-A1 Synthetic antigens for the detection of aids-related disease caused by LAV-2 GENETIC SYSTEMS CORPORATION (US) 1988-09-28 EP disclosed
EP-0267802-A2 Synthetic antigen for the detection of aids-related disease GENETIC SYSTEMS CORPORATION (US) 1988-05-18 EP disclosed
EP-0220273-A1 SYNTHETIC ANTIGENS FOR THE DETECTION OF AIDS-RELATED DISEASE. GENETIC SYSTEMS CORP (US) 1987-05-06 EP disclosed
EP-0212404-A1 7-oxo-4-thia-1-azabicyclo [3.2.0] hept-2-ene derivatives HOECHST AKTIENGESELLSCHAFT (DE) 1987-03-04 EP disclosed
US-4629783-A POLYPEPTIDES GENETIC SYSTEMS CORPORATION (US) 1986-12-16 US disclosed
WO-1986006414-A1 SYNTHETIC ANTIGENS FOR THE DETECTION OF AIDS-RELATED DISEASE GENETIC SYSTEMS CORPORATION (US) 1986-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10190952-B2 Guest-compound-enveloping polymer-metal-complex crystal, method for producing same, method for preparing crystal structure analysis sample, and method for determining molecular structure of organic compound MLEC, MCM4, PICALM ALDH1A1 4366/4885CES2 2322/4885CES1 3386/4885
US-10684198-B2 Guest-compound-enveloping polymer-metal-complex crystal, method for producing same, method for preparing crystal structure analysis sample, and method for determining molecular structure of organic compound TPR, MCM6, MCM5 ALDH1A1 4624/4885CES2 3121/4885CES1 4670/4885
US-20190137367-A1 GUEST-COMPOUND-ENVELOPING POLYMER-METAL-COMPLEX CRYSTAL, METHOD FOR PRODUCING SAME, METHOD FOR PREPARING CRYSTAL STRUCTURE ANALYSIS SAMPLE, AND METHOD FOR DETERMINING MOLECULAR STRUCTURE OF ORGANIC COMPOUND TPR, MCM6, MCM5 ALDH1A1 4624/4885CES2 3121/4885CES1 4670/4885
US-20230119325-A1 GLYCOTARGETING THERAPEUTICS LGALS3BP, LGALS1, CD47 ALDH1A1 1840/4885CES2 1557/4885CES1 696/4885
US-10953101-B2 Glycotargeting therapeutics LGALS3BP, LGALS1, CD47 ALDH1A1 1840/4885CES2 1557/4885CES1 696/4885
US-10487420-B2 Single crystal of porous compound, method for assessing quality of single crystal, method for preparing solution including compound to be analyzed, method for producing crystal structure analysis sample, and method for determining molecular structure of compound to be analyzed CXCR5, CXCR6, CXCR1 ALDH1A1 4527/4885CES2 4142/4885CES1 4732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.